The FDA has slapped a clinical hold on Rocket Pharmaceuticals’ pivotal gene therapy trial in response to a death. Rocket, ...

Nice 23andMe sale hearing ya got there — shame if something happened to it, say attorneys for co-founder and former CEO who ...

Sanofi’s plans to submit itepekimab to regulators for approval this year have been thrown into doubt after the ...

Shares Biotechnology ETF offers efficient, diversified exposure to the sector's revival, balancing risk and cost for ...

Michael Yee, Jefferies senior biotech analyst, joins CNBC's 'Squawk on the Street' to discuss how AI could fuel drug ...

(SMMT) stock rises as its lung cancer drug ivonescimab with chemotherapy hit the main goal in a Phase 3 trial for lung cancer ...

The Polar report also examines growth drivers, including the dynamic food and beverage industry, stringent food safety ...

Artificial Intelligence (AI) has rapidly evolved from a promising technology to a core enabler of innovation in the pharmaceutical industry. Today, AI is estimated to generate between $350 billion and ...

Rocket Pharmaceuticals faces trial delays, multiple downgrades, and reduced success expectations following RP-A501 safety ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has entered a key licensing agreement with Telesis Bio Inc. to integrate the ...

Archaeologists uncovered traces of early civilization at Mount Tai, China, offering new insights into social structure, ...